Pharmacologic management of type 2 diabetes in the elderly: Overview of treatment options

Formulary

Volumn 35, Issue 7, 2000, Pages 580-594

  Da Silva, Barbara A ^a   Molitch, Mark E ^b  

^a PFIZER INC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; MIGLITOL; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC DIET; HYPOGLYCEMIA; INSULIN TREATMENT; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; WEIGHT REDUCTION;

EID: 0033927854     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Defronzo RA. Pharmacological therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
2. Yoon J-W, Ihm S-H. Modern concepts in the etiology of IDDM: Genes, viruses, autoimmunity. In: Tze WJ, Sima AAF, Tai J, eds. Insulin-Dependent Diabetes Mellitus: Current Concepts and Approaches. Montreal, Canada: Rodar Publishing; 1991:1-16.
3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-26.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
5. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 1990;13:992-1010.
6. Defronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetic genes. Diabetes Rev 1997;5:177-269.
7. Ratner RE. Type 2 diabetes mellitus: The grand overview. Diabet Med 1998;15:54-7.
8. American Diabetes Association Position Statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23:S32-S42.
9. Reed RL, Mooradian AD. Primary Care Geriatrics. St.Louis, MO: Mosby-Year Book; 1997:441.
10. Morley JE, Mooradian AD, Rosenthal MJ, Kaiser FK. Diabetes in elderly patients: Is it different?. Am J Med 1987;83:533-44.
11. Morley JE. The elderly type 2 diabetic patient: Special considerations. Diabet Med 1998;15(Suppl):S41-S45.
12. Naliboff BD, Rosenthal M. Effects of age on complications in adult-onset diabetes. J Am Geriatr Soc 1989;37:838-42.
13. Meneilly GS, Tessier D. Diabetes in the elderly. Diabet Med 1995;12:949-60.
14. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995:233-57. NIH publication 94-1468.
15. Morley JE, Perry HM III. The management of diabetes mellitus in older individuals. Drugs 1991;41:548-65.
16. Singh I, Marshall MC Jr. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 1995;24:255-72.
17. Asplund K, Wilholm BE, Lithner F. Glibenclimide-associated hypoglycemia: A report on 57 cases. Diabetologia 1983;24:412-7.
18. Stepka M, Rogala H, Czyzyk A. Hypoglycemia: A major problem in the management of diabetes in the elderly. Aging 1993;5:117-21.
19. Mooradian AD, Perryman K, Filler J, et al. Cortical function in elderly non-insulin-dependent diabetic patients. Behavioral and electrophysiological studies. Arch Intern Med 1988;148:2369-72.
20. Morley JE, Flood JF. Psychological aspects of diabetes mellitus in older persons. J Am Geriatr Soc 1990;38:605-6.
21. Peyrot M, Rubin RR. Persistence of depressive symptoms in diabetic adults. Diabetes Care 1999;22:448-52.
22. Trends in the Health of Older Americans: United States, 1994. Washington, DC: National Center for Health Statistics; 1995.
23. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
24. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
25. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
26. Campbell LK, White JR, Campbell RK. Acarbose: Its role in the treatment of diabetes mellitus. Ann Pharmacother 1996;30:1255-61.
27. Edelman SV. New orally administered antihyperglycemic agents in patients with type 2 diabetes and the syndrome of insulin resistance. Endocrine Pract 1996;2:271-75.
28. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994;122:928-35.
29. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442-8.
30. Zimmerman BR. Treatment options for NIDDM. In: Mediguide to Diabetes. Whitehouse FW, ed. New York, NY: Lawrence Della Corte Publications; 1996:1-8.
31. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetics shows improved glycemic control over 3 years. Diabetes Care 1999;22:960-4.
32. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-21.
33. Lipsky MS, Zimmerman BR. Diagnosis and management of type 2 diabetes. American Family Physician; monograph 1; 1999.
34. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
35. Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10:671-8.
36. Damsbo P, Clauson P, Marbury TC, Winfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999;22:789-94.
37. Defronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent subjects. J Clin Endocrinol Metab 1991;73:1294-301.
38. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type 2 diabetes: Results of a double-blind placebo-controlled dose-response trial. Am J Med 1997;103:491-7.
39. Johansen K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999; 22:33-44.
40. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-62.
41. Peters A, Kerner W. Perioperative management of the diabetic patient. Exp Clin Endocrinol Diabetes 1995;103:213-8.
42. Lambe KG, Tugwood JD. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis including thiazolidinedione drugs. Eur J Biochem 1996;239:1-7.
43. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-12.
44. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisomal proliferator-activating receptors and liver X receptor-a in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-27.
45. Buse JB, Faja BW, Gumbiner B, et al. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998;21:1455-61.
46. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Engl J Med 1998;338:861-6.
47. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921-30.
48. Nozue T, Michishita I, Minagawa F, Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999;22:355-6.
49. Lumpkin MM. Troglitazone. Presentation to FDA Advisory Committee; Washington, DC; May 19, 2000.
50. Henry RR. Thiazoladinediones. Endocrinol Clin North Am 1997;26:553-73.
51. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 1997;26:575-97.
52. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22(Suppl 2):B109-13.
53. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-96.
54. Eastman RC, Dong F, Javitt JC, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44.
55. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998;317:720-6.
56. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390-404.
57. Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2000.